AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03160339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0047 Vaccine
Description: PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
Study NCT03666572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
Description: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]
Study NCT03666572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Lactose)
Description: Placebo (Lactose)
Study NCT03160339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Teva Ad4/Ad7 Vaccine
Description: Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
Study NCT04220762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-1001X
Description: This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
Study NCT04220762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
Study NCT01815762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active arm
Description: In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication.
Study NCT02271776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galactooligosaccharide
Description: The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
Study NCT02271776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Study NCT00365677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm
Description: Used with LASIK treatment for the correction of myopia and myopic astigmatism.
Study NCT01204177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766 MEK Inhibitor + Sorafenib
Description: All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
Study NCT02098746 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone/glimepiride
Description: Pioglitazone/glimepiride combination tablets
Study NCT00365677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Bausch & Lomb Zyoptix Tissue Saving algorithm
Description: Used with LASIK treatment for the correction of myopia and myopic astigmatism.
Study NCT04689282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).
Description: Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Study NCT01773486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Citrus polyphenol, hesperidin
Study NCT01773486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching hesperidin
Study NCT01729286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PriMatrix Moist Wound Therapy
Description: sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
Study NCT01729286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Moist Wound Therapy
Description: sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
Study NCT01729286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Moist Wound Therapy
Description: sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
Study NCT00247403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-deoxyglucose (2DG)
Description: Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
Study NCT01107951 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab and dexamethasone
Description: Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)
Study NCT01230463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
Study NCT01230463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
Study NCT02697370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacokinetic based dosage change
Description: Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
Study NCT03527238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPM-based Computation Assisted Drug Dosing
Description: Tacrolimus dosing based on application of PPM.
Study NCT03527238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Dosing of calcineurin inhibitor, tacrolimus
Study NCT03527238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosing of calcineurin inhibitor, tacrolimus
Study NCT02169167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin salve treatment
Description: Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
Study NCT02169167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Octenidine treatment
Description: Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
Study NCT02174666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red clover extract
Description: Aglycone isoflavones 80mg/d
Study NCT02174666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplementation (placebo)
Study NCT03170791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagal nerve stimulation intervention
Description: During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
Study NCT02665338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT02665338 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study NCT05299593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafluprost/timolol
Description: One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day.
Study NCT02239900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.~Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.~Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4
Study NCT02239900 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.~Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.~Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
Study NCT02469857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB103 0.5 mg/kg
Study NCT02469857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Study NCT01710423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention ('Cooking with Friends')
Description: 'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children.
Study NCT03749161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-add multifocal IOL
Description: Lentis comfort, low-add multifocal, IOL
Study NCT03749161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofocal IOL
Description: Lentis L-313, monofocal IOL
Study NCT03493971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid revascularization performed using CAS
Description: Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
Study NCT03493971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid revascularization performed using CEA
Description: Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
Study NCT03183206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery , IRE surgery ,surgery
Description: surgery will be used in local tumor
Study NCT03183206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cells
Description: γδ T cells will be used against
Study NCT03183206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: γδ T cells/ Surgery
Description: Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
Study NCT03409380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine Drink
Description: 10 g of arginine in a formulated drink
Study NCT03409380 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain Drink
Description: formulated drink
Study NCT03418519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy
Study NCT00516646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALT-711
Description: 200 mg bid
Study NCT00516646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: bid
Study NCT02737137 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Manual measurement
Description: Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
Study NCT02737137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement with a gauge
Description: Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
Study NCT03502798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scanning a/LCI
Description: Imaging of the cervical epithelium using the scanning a/LCI device.
Study NCT04186156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KA2507
Description: KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
Study NCT02640560 — intervention group
Intervention type: OTHER
Intervention: Food allergy questionnaire
Description: The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
Study NCT02640560 — intervention group
Intervention type: OTHER
Intervention: Control Questionnaire
Description: The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
Study NCT01344564 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Degarelix acetate, Leuprolide acetate
Description: Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
Study NCT02774083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feuerstein Program
Description: Mediated learning cognitive enhancement program
Study NCT02774083 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Adler Program
Description: Social and emotional group program
Study NCT03213717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Casall HIT weight vest
Description: A weight west with a weight of 10 % compared to the study subject
Study NCT03213717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Study subjects will be standing for at least 50 minutes every hour
Study NCT03213717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standing
Description: Study subjects will be standing for at least 50 minutes every hour
Study NCT03213717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water load
Description: Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
Study NCT03213717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water load
Description: Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
Study NCT03213717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: Study subjects will be sitting for at least 50 minutes of every hour
Study NCT03213717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Casall HIT weight vest
Description: A weight west with a weight of 1 % compared to the study subject
Study NCT04023578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHEO KNEE XC
Description: Microprocessor controlled knee using Magneto-Rheologic techonology.
Study NCT01563081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
Study NCT01563081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
Study NCT02171455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low dose
Study NCT02171455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate medium dose
Study NCT02171455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose
Study NCT02171455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02141932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bed-side pocket size ultrasound imaging
Study NCT02141932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Ultrasound Vscan
Study NCT03430739 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01026493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 60 mg x 21 days
Description: Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
Study NCT01026493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 75 mg x 21 days
Description: Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
Study NCT01026493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 20 mg x 21 days
Description: 20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
Study NCT01026493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 21 days
Description: 40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
Study NCT03923790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Packet
Description: The patient will receive an educational packet.
Study NCT03923790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Packet
Description: The patient will receive an educational packet.